Kinfo
Codexis Inc. logo

Codexis Inc.

CDXSNASDAQHealthcare·US · USD
$1.60
+0.00 (+0.00%)
Prices as of August 13, 2026 · market closed

Price

Key statistics

Valuation
Market cap172.10M USD
Enterprise value142.29M USD
Trailing P/E-3.19
Forward P/E-4.32
PEG ratio0.05
Price / sales2.20
Price / book3.36
Profitability
Gross margin86.46%
Operating margin-52.75%
Profit margin-40.97%
Return on assets-12.53%
Return on equity-68.90%
Income (TTM)
Revenue78.09M USD
Gross profit18.61M USD
EBITDA-20.55M USD
Net income-31.99M USD
Diluted EPS-$0.33
Rev. growth (YoY)102.10%
Balance sheet
Total cash65.14M USD
Total debt72.90M USD
Debt / equity168.62
Current ratio5.36
Book value / share$0.48
Cash flow (TTM)
Operating cash flow-18.73M USD
Levered free cash flow-8.48M USD
Shares & price
Shares outstanding90.89M
Float73.47M
Held by institutions71.57%
Beta2.50
50-day MA$2.17
200-day MA$1.93
52-week high$3.87
52-week low$0.96
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-11-0.12-0.13−8.33%2026-07-280.870.89+2.30%2026-05-07-0.10-0.10+0.00%2026-03-11-0.040.14+450.00%2026-01-231.611.87+16.15%
About Codexis Inc.

Codexis Inc. is a leading enzyme engineering company that develops scalable, sustainable enzymatic solutions for therapeutic manufacturing and development. It leverages the proprietary CodeEvolver protein engineering technology platform to design and optimize novel enzymes that outperform traditional methods, enabling efficient production with fewer impurities, reduced waste, and lower energy use. The company operates through two main segments: Performance Enzymes, which commercializes enzyme products and technologies primarily for the pharmaceuticals market, including applications in RNAi therapeutics manufacturing via the ECO Synthesis platform; and Novel Biotherapeutics, which focuses on discovering and improving biotherapeutic drug candidates. Codexis Inc. also provides enzymes for precision diagnostics, such as Codex HiFi Hot Start DNA Polymerase and screening kits, along with services supporting small molecule manufacturing. These offerings serve partners in therapeutics development across regions including the United States, Europe, Asia, and beyond. Founded in 2002 and headquartered in Redwood City, California, Codexis Inc. plays a key role in advancing enzymatic manufacturing innovations for the biotechnology and pharmaceutical industries.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alison Moore Ph.D.
Employees
146
Headquarters
Redwood City, CA, United States

Frequently asked questions about Codexis Inc.